Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

OSEO awards fund for Galapagos NV's antibody therapeutics program

Galapagos NV announces that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO.

26 Nov 2009

Scientists offer first genetic proof of new and rational treatment for osteoporosis

The so-called RANK protein and the molecule that binds to it, the RANK ligand or RANKL, form a focus of the work of Josef Penninger, director of the Institute of Molecular Biotechnology (IMBA) in Vienna. In 1999 his group deleted the RANKL gene from mice and showed that the RANK/RANKL system was the "master regulator" governing bone loss (Kong et al. 1999 Nature 402, 304-309).

26 Nov 2009

Erbitux drug can reverse rare stomach disorder, report researchers

A drug used to treat colorectal cancer also can reverse a rare stomach disorder and should be considered first-line therapy for the disease, researchers at Vanderbilt University Medical Center report this week.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

25 Nov 2009

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups

25 Nov 2009

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

The Lupus Research Institute (LRI) today named 12 new grant recipients for 2009. The awards, totaling $3.6 million, recognize innovative work across a broad spectrum of lupus research. All were selected for their creativity, novelty, and potential to drive scientific discovery to ultimately prevent, treat, and cure the complex disease of systemic lupus.

24 Nov 2009

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

AVANIR Pharmaceuticals, Inc. today reported unaudited financial results for the three and twelve months ended September 30, 2009.

24 Nov 2009

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced three new studies that demonstrate the clinical utility of PillCam SB capsule endoscopy in providing physicians with critical information on how they manage and/or diagnose intestinal disorders. These novel studies were carried out in pediatric patients with gastrointestinal symptoms, including children with known or suspected Crohn's disease.

24 Nov 2009

TAP delivers customized automated protein purification system in collaboration with a European major

The Automation Partnership (TAP), a world leader in the design and development of innovative automation for life science applications, today announced its Advanced Projects Group has successfully collaborated with a major European antibody therapeutics company to deliver a custom automated protein purification and concentration system helping the company accelerate its pre-clinical research.

24 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics SA (formerly known as Protein’eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.

24 Nov 2009

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

23 Nov 2009

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.

23 Nov 2009

MMR Information Systems to add new feature in its personal health record website

MMR Information Systems, Inc. announced today it will add a clinical trials information service to its MyMedicalRecords Personal Health Record site, www.mymedicalrecords.com.

23 Nov 2009

New FluCide better than the older version

NanoViricides, Inc., announced today that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC (www.terrapinn.com/usaflu). These data clearly established that the new version of FluCide™ is superior to the older version.

23 Nov 2009

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Human Genome Sciences, Inc. and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.

23 Nov 2009

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells.

23 Nov 2009

UT Southwestern Medical Center receives NIH funds for asthma research

UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

23 Nov 2009

Antibody News and Research

Further Reading

OSEO awards fund for Galapagos NV's antibody therapeutics program

Scientists offer first genetic proof of new and rational treatment for osteoporosis

Erbitux drug can reverse rare stomach disorder, report researchers

Human Genome Sciences submits BLA for ZALBIN

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

EMEA grants orphan drug status for LFB Biotechnologies' recombinant anti-CD20 monoclonal antibody

Comparison study finds no significant differences in post-transplant survival rates of NASH and ETOH groups

LRI awards $3.6 million grants to drive innovative science in lupus and related diseases

Fourth-quarter and full year fiscal 2009 results announced by AVANIR Pharmaceuticals

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

TAP delivers customized automated protein purification system in collaboration with a European major

Seattle Genetics and Agensys expand ADC collaboration

PX’Therapeutics sets up additional biomanufacturing unit

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

MMR Information Systems to add new feature in its personal health record website

New FluCide better than the older version

Human Genome Sciences commences patient dosing in its HGS1029 inhibitor trial

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

UT Southwestern Medical Center receives NIH funds for asthma research

How to make hybridoma-based antibody discovery more efficient eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News